NEWSFLASH! Erysdi PBS Listing Expansion – 3 copies SMN2

1 November 2024

Today, the Pharmaceutical Benefits Scheme (PBS) expanded its listing for Evrysdi (Risdiplam) to include pre-symptomatic babies with three copies of the SMN2 gene.

This is excellent news for these infants, as they now have three available treatment options following the PBS listings of Zolgensma in October 2023 and Spinraza in March 2024. These advancements significantly enhance the treatment landscape for SMA and offer hope for better outcomes.